All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
EMA CHMP grants positive opinion to dara-VTd combination for patients with newly diagnosed, transplant eligible multiple myeloma
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the combination of daratumumab (dara), bortezomib (V), thalidomide (T) and dexamethasone (d, dara-VTd) for patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant (ASCT).1 The United States (U.S.) Food & Drug Administration (FDA) approved the dara-VTd combination in the same setting earlier this year in September 2019.2
The decisions of the EMA and FDA are based on the results of part one of the phase III CASSIOPEIA trial, presented during the American Society of Clinical Oncology (ASCO) meeting by Professor Philippe Moreau, earlier this year.3
CASSIOPEIA3,4
CASSIOPEIA is a phase III randomized trial comparing dara-VTd (n= 543) to VTd (n= 542) alone in patients with NDMM who are eligible for ASCT. At a median follow-up of 18.8 months, the rate of stringent complete response (sCR) was higher in the dara-VTd arm (29%) compared to VTd alone (20%). Measurable residual disease (MRD) negative rates were also higher in the dara-VTd group (64%) compared to the VTd arm (44%). Progression-free survival (PFS) at 18 months was 93% with dara-VTd versus 85% with VTd. This equated to a 53% reduction in the risk of progression or death. Median overall survival was not reached in either arm, with a 24-month OS rate of 97% with dara-VTd and 93% with VTd. The safety profile of the quadruplet regimen was equivalent to the drugs when given as single agents or combination therapies. Read more about the results of part one of the CASSIOPEIA trial here.3
Part two of the CASSIOPEIA trial is ongoing, with patients who achieve a response to induction and consolidation being re-randomized to maintenance with daratumumab (16mg/kg every eight weeks for up to two years), or observation. The primary endpoint of part two is post-maintenance progression-free survival.4
References